Article info
Therapeutic Intervention
Multiple sclerosis therapy: new agents carry new risks
- Correspondence to: Dr R Gold, Department of Experimental and Clinical Neuroimmunology, Institute for MS-Research, Waldweg 33, 37073, Göttingen, Germany r.gold{at}med.uni-goettingen.de
Citation
Multiple sclerosis therapy: new agents carry new risks
Publication history
- First published July 17, 2006.
Online issue publication
July 17, 2006
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 Journal of Neurology Neurosurgery and Psychiatry
Other content recommended for you
- Natalizumab and progressive multifocal leucoencephalopathy
- Lessons for clinical trials from natalizumab in multiple sclerosis
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Extended interval dosing of natalizumab in multiple sclerosis
- Update on disease-modifying therapies for multiple sclerosis
- Changes to anti-JCV antibody levels in a Swedish national MS cohort